Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573558 | 1.00 | RPS6KA3 (0.43) | RPS6KA3MAPTSMN1; SMN2POLBTDP1 | |
| SCHEMBL915472 | 0.90 | MAPT (0.39) | RPS6KA3MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL915474 | 0.90 | MAPT (0.39) | RPS6KA3MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL7747059 | 0.88 | POLB (0.46) | RPS6KA3MAPTSMN1; SMN2POLBTDP1 | |
| SCHEMBL7747061 | 0.88 | POLB (0.46) | RPS6KA3MAPTSMN1; SMN2POLBTDP1 | |
| SCHEMBL5574487 | 0.87 | LMNA (0.45) | RPS6KA3MAPTSMN1; SMN2POLBTDP1 | |
| SCHEMBL5574491 | 0.87 | LMNA (0.45) | RPS6KA3MAPTSMN1; SMN2POLBTDP1 | |
| SCHEMBL5573564 | 0.83 | POLB (0.45) | MAPTSMN1; SMN2POLBTDP1KMT2A | |
| SCHEMBL14806594 | 0.82 | MAPT (0.43) | MAPTSMN1; SMN2POLBTDP1KMT2A | |
| SCHEMBL14806593 | 0.82 | MAPT (0.43) | MAPTSMN1; SMN2POLBTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070231267-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231267-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | RPS6KA3 1383/4885MAPT 4502/4885SMN1; SMN2 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.